Skip to main content
Withus Pharmaceutical. Co., LTD logo

Withus Pharmaceutical. Co., LTD — Investor Relations & Filings

Ticker · 330350 ISIN · KR7330350000 KO Manufacturing
Open in API
Filings indexed 120 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 330350

About Withus Pharmaceutical. Co., LTD

https://withuspharm.com/

Withus Pharmaceutical. Co., LTD. is a pharmaceutical company engaged in the manufacturing and sale of prescription drugs. The company's product portfolio addresses a range of therapeutic areas, with a focus on circulatory agents, endocrine system treatments, and musculoskeletal drugs. Additionally, its offerings include antibiotics and medications for allergies.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서” covering the period January 1, 2026 to March 31, 2026 (1Q of fiscal year), contains detailed narrative and comprehensive financial tables (revenue by product line, production capacity, inventories, capital changes, etc.). This is a full quarterly (interim) report rather than a brief announcement. Hence it matches the Interim/Quarterly Report category. Q1 2026
2026-05-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled “정기주주총회결과” (Regular Shareholders’ Meeting Results) and contains the approval of financial statements, dividend decisions, officer appointments, record date, meeting date, and detailed voting outcomes (agenda items, voting percentages, pass/fail status). This is a declaration of the voting results from a general meeting rather than the full AGM materials or a regulatory notice. Therefore, it matches the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-26 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 98% confidence The document is a formal 'Audit Report' (감사보고서) for Withus Pharmaceutical Co., Ltd. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It covers the fiscal period from January 1, 2025, to December 31, 2025. While it contains financial statements, it is explicitly titled as an Audit Report and includes the auditor's opinion, which aligns with the 'AR' (Audit Report / Information) category rather than a full 10-K annual report, as it focuses on the audit process and results. FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a regulatory filing from a Korean company (Withus Pharmaceutical) titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, revenue, profit), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report to the exchange, rather than the full annual report or a standalone audit report document. Under the 'Menu vs Meal' rule, this is a formal notification of the filing of the audit report. FY 2025
2026-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Withus Pharmaceutical Co., Ltd. It contains the agenda for the 22nd Annual General Meeting, including reports on audit, business, and financial statements, as well as proposals for approval of financial statements and director/auditor remuneration. It also includes detailed financial statements (balance sheet, income statement, etc.) as part of the 'management reference materials' required for shareholder review prior to the meeting. This is a standard proxy solicitation document used to inform shareholders of an upcoming meeting and provide necessary information for voting.
2026-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Withus Pharmaceutical. It outlines the date, time, location, and the agenda items (financial statement approval, director/auditor compensation limits). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-03-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.